News Headlines Article

Blue Shield of California CEO: Hepatitis C pill shows drug pricing is ‘broken’
San Francisco Chronicle

The head of Blue Shield of California on Monday said Gilead Sciences’ controversial hepatitis C drug is unsustainable at $1,000 a day, joining a growing chorus of payers who are unhappy with the price.

“How much can we afford to pay for one drug? How much profit does one company deserve for producing that drug?” wrote President and CEO Paul Markovich in an editorial that appeared exclusively in The Chronicle. “With last month’s release of record earnings for Gilead Sciences — nearly $6 billion in profits in half a year from the hepatitis C drug, Sovaldi, these questions need to be answered.”